See more : Lifestyle Communities Limited (LCOMF) Income Statement Analysis – Financial Results
Complete financial analysis of Quest Diagnostics Incorporated (DGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quest Diagnostics Incorporated, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Man Wah Holdings Limited (1999.HK) Income Statement Analysis – Financial Results
- Indra Sistemas, S.A. (ISMAY) Income Statement Analysis – Financial Results
- Public Joint Stock Company Severstal (SVST.IL) Income Statement Analysis – Financial Results
- Dah Sing Financial Holdings Limited (DAHSF) Income Statement Analysis – Financial Results
- Valdor Technology International Inc. (VTI.CN) Income Statement Analysis – Financial Results
Quest Diagnostics Incorporated (DGX)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.questdiagnostics.com
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.25B | 9.88B | 10.79B | 9.44B | 7.73B | 7.53B | 7.71B | 7.52B | 7.49B | 7.44B | 7.15B | 7.38B | 7.51B | 7.37B | 7.46B | 7.25B | 6.70B | 6.27B | 5.50B | 5.13B | 4.74B | 4.11B | 3.63B | 3.42B | 2.21B | 1.46B | 1.53B | 1.62B |
| Cost of Revenue | 6.29B | 6.45B | 6.58B | 5.80B | 5.04B | 4.93B | 4.72B | 4.62B | 4.66B | 4.64B | 4.33B | 4.36B | 4.40B | 4.32B | 4.32B | 4.26B | 3.97B | 3.70B | 3.26B | 2.99B | 2.77B | 2.43B | 2.15B | 1.97B | 1.32B | 813.90M | 875.50M | 1.01B |
| Gross Profit | 2.96B | 3.43B | 4.21B | 3.63B | 2.69B | 2.61B | 2.99B | 2.90B | 2.84B | 2.80B | 2.82B | 3.02B | 3.12B | 3.05B | 3.13B | 2.99B | 2.74B | 2.57B | 2.25B | 2.14B | 1.97B | 1.68B | 1.48B | 1.45B | 886.20M | 644.70M | 653.20M | 605.42M |
| Gross Profit Ratio | 32.00% | 34.74% | 39.02% | 38.50% | 34.80% | 34.59% | 38.79% | 38.58% | 37.85% | 37.63% | 39.46% | 40.88% | 41.48% | 41.41% | 42.03% | 41.29% | 40.79% | 41.04% | 40.82% | 41.66% | 41.57% | 40.79% | 40.69% | 42.49% | 40.19% | 44.20% | 42.73% | 37.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00K | 27.00K | -18.00K | -34.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.62B | 1.87B | 1.73B | 1.55B | 1.46B | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Other Expenses | 0.00 | 131.00M | 101.00M | 112.00M | 1.00M | -8.00M | 16.00M | -48.00M | -143.00M | 4.00M | 8.00M | 6.70M | 305.79M | 48.47M | 27.04M | 33.98M | 30.87M | 10.91M | 20.49M | 6.70M | 8.20M | 8.37M | 46.11M | 134.30M | 90.80M | 68.80M | 76.40M | 711.38M |
| Operating Expenses | 1.76B | 2.01B | 1.83B | 1.66B | 1.46B | 1.50B | 1.83B | 1.74B | 1.77B | 1.82B | 1.82B | 1.82B | 2.12B | 1.76B | 1.77B | 1.77B | 1.64B | 1.44B | 1.28B | 1.23B | 1.17B | 1.08B | 1.06B | 1.14B | 734.20M | 550.40M | 578.50M | 1.21B |
| Cost & Expenses | 7.94B | 8.46B | 8.41B | 7.47B | 6.50B | 6.43B | 6.54B | 6.36B | 6.43B | 6.45B | 6.15B | 6.18B | 6.52B | 6.07B | 6.10B | 6.03B | 5.61B | 5.14B | 4.54B | 4.23B | 3.94B | 3.52B | 3.22B | 3.10B | 2.05B | 1.36B | 1.45B | 2.22B |
| Interest Income | 11.00M | 10.00M | 1.00M | 3.00M | 5.00M | 2.00M | 2.00M | 1.00M | 1.00M | 3.00M | 3.00M | 3.00M | 2.77M | 1.41M | 2.52M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 163.00M | 138.00M | 151.00M | 163.00M | 175.00M | 167.00M | 151.00M | 143.00M | 153.00M | 164.00M | 159.00M | 164.70M | 170.60M | 146.10M | 144.10M | 185.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 439.00M | 437.00M | 408.00M | 361.00M | 329.00M | 309.00M | 270.00M | 249.00M | 304.00M | 314.00M | 283.00M | 286.60M | 281.10M | 254.00M | 256.70M | 264.60M | 237.88M | 197.40M | 176.12M | 168.73M | 153.90M | 131.39M | 147.73M | 134.30M | 90.80M | 68.80M | 76.40M | 99.10M |
| EBITDA | 1.73B | 1.82B | 3.16B | 2.41B | 1.59B | 1.40B | 1.45B | 1.48B | 1.56B | 1.30B | 1.79B | 1.52B | 1.30B | 1.59B | 1.63B | 1.50B | 1.33B | 1.33B | 1.18B | 1.05B | 950.36M | 723.84M | 559.12M | 452.11M | 242.80M | 163.10M | 151.10M | -502.19M |
| EBITDA Ratio | 18.72% | 18.31% | 29.27% | 25.52% | 20.45% | 18.67% | 18.82% | 18.10% | 20.82% | 17.85% | 18.42% | 20.58% | 17.38% | 21.43% | 22.12% | 21.25% | 19.88% | 21.27% | 21.20% | 21.07% | 19.99% | 17.17% | 15.37% | 13.32% | 14.46% | 11.66% | 13.34% | -31.07% |
| Operating Income | 1.26B | 1.43B | 2.38B | 1.97B | 1.23B | 1.10B | 1.17B | 1.28B | 1.40B | 983.00M | 1.48B | 1.20B | 995.00M | 1.30B | 1.36B | 1.22B | 1.09B | 1.13B | 968.11M | 901.44M | 795.43M | 592.45M | 411.39M | 317.82M | 152.00M | 94.30M | 74.70M | -601.28M |
| Operating Income Ratio | 13.64% | 14.45% | 22.07% | 20.89% | 15.93% | 14.62% | 15.11% | 16.99% | 18.67% | 13.22% | 20.64% | 16.27% | 13.25% | 17.58% | 18.23% | 16.86% | 16.28% | 17.99% | 17.59% | 17.58% | 16.79% | 14.42% | 11.34% | 9.29% | 6.89% | 6.47% | 4.89% | -37.20% |
| Total Other Income/Expenses | -132.00M | -193.00M | 218.00M | -87.00M | -155.00M | -175.00M | -135.00M | -142.00M | -101.00M | -134.00M | 192.00M | -133.00M | -130.77M | -99.28M | -131.18M | -203.42M | -178.93M | -94.73M | -57.66M | -76.55M | -58.66M | -50.07M | -114.80M | -116.84M | -137.60M | -40.40M | -93.80M | -74.92M |
| Income Before Tax | 1.13B | 1.24B | 2.60B | 1.88B | 1.08B | 926.00M | 1.03B | 1.09B | 1.10B | 849.00M | 1.35B | 1.07B | 856.30M | 1.18B | 1.23B | 1.02B | 912.40M | 1.03B | 910.45M | 835.13M | 737.80M | 542.38M | 332.60M | 200.98M | 14.40M | 53.90M | -19.10M | -676.20M |
| Income Before Tax Ratio | 12.21% | 12.50% | 24.09% | 19.96% | 13.93% | 12.30% | 13.36% | 14.45% | 14.72% | 11.42% | 18.86% | 14.47% | 11.40% | 16.07% | 16.47% | 14.06% | 13.61% | 16.48% | 16.54% | 16.29% | 15.57% | 13.20% | 9.17% | 5.87% | 0.65% | 3.70% | -1.25% | -41.84% |
| Income Tax Expense | 248.00M | 264.00M | 597.00M | 460.00M | 247.00M | 182.00M | 241.00M | 429.00M | 373.00M | 262.00M | 500.00M | 401.90M | 349.00M | 425.50M | 460.40M | 386.80M | 358.57M | 407.58M | 364.18M | 335.93M | 301.08M | 220.22M | 148.69M | 96.03M | 15.70M | 27.00M | 3.20M | -50.24M |
| Net Income | 854.00M | 946.00M | 2.00B | 1.43B | 858.00M | 736.00M | 772.00M | 645.00M | 709.00M | 556.00M | 849.00M | 555.70M | 470.60M | 720.90M | 729.10M | 581.50M | 339.94M | 586.42M | 546.28M | 499.20M | 436.72M | 322.15M | 162.30M | 102.05M | -3.40M | 26.90M | -22.30M | -625.96M |
| Net Income Ratio | 9.23% | 9.57% | 18.49% | 15.16% | 11.11% | 9.77% | 10.01% | 8.58% | 9.46% | 7.48% | 11.88% | 7.53% | 6.27% | 9.78% | 9.78% | 8.02% | 5.07% | 9.35% | 9.93% | 9.74% | 9.22% | 7.84% | 4.47% | 2.98% | -0.15% | 1.84% | -1.46% | -38.73% |
| EPS | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.41 | 5.63 | 4.58 | 4.92 | 3.83 | 5.58 | 3.49 | 2.95 | 4.08 | 3.91 | 2.99 | 1.76 | 2.98 | 2.71 | 2.45 | 2.11 | 1.67 | 0.87 | 0.57 | -0.03 | 0.23 | -0.19 | -5.33 |
| EPS Diluted | 7.52 | 7.98 | 15.53 | 10.52 | 6.29 | 5.29 | 5.50 | 4.51 | 4.87 | 3.81 | 5.54 | 3.46 | 2.92 | 4.05 | 3.87 | 2.97 | 1.74 | 2.94 | 2.66 | 2.35 | 2.02 | 1.62 | 0.83 | 0.54 | -0.03 | 0.22 | -0.19 | -5.33 |
| Weighted Avg Shares Out | 112.00M | 116.00M | 125.00M | 134.00M | 134.00M | 136.00M | 137.00M | 140.00M | 144.00M | 145.00M | 152.00M | 158.60M | 158.70M | 175.70M | 185.90M | 194.30M | 193.24M | 196.99M | 201.83M | 203.75M | 206.97M | 192.91M | 186.56M | 179.04M | 136.00M | 119.56M | 115.84M | 117.45M |
| Weighted Avg Shares Out (Dil) | 113.00M | 118.00M | 128.00M | 136.00M | 136.00M | 139.00M | 140.00M | 142.00M | 145.00M | 145.00M | 153.00M | 160.10M | 160.20M | 177.30M | 187.80M | 196.00M | 195.26M | 199.54M | 205.53M | 212.42M | 216.20M | 199.48M | 195.55M | 188.99M | 136.00M | 120.90M | 116.15M | 117.45M |
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base
Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLabs acquisition, aims to expand its footprint and diversify operations, despite short-term EPS...
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue...
DGX or PNTG: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking...
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.
US lab operator Quest Diagnostics to launch bird flu test at end of October
Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging...
Quest Diagnostics Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development
Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month based on one of the awards SECAUCUS, N.J. , Oct. 23, 2024 /PRNewswire/...
Overlooked Stock: DGX
One of the biggest earnings movers from Tuesday: Quest Diagnostics (DGX). The lab & testing company beat on the top-and-bottom line in its 3Q report, as shares surged to multi-month highs.
Quest Diagnostics (DGX) Q3 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice President, Chief Financial Officer Shawn Bevec - Vice President, Investor...
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics Inc DGX posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.
Source: https://incomestatements.info
Category: Stock Reports